Published in Pediatr Blood Cancer on February 01, 2010
Hydroxyurea to Prevent Organ Damage in Children With Sickle Cell Anemia | NCT00006400
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood (2012) 1.66
Renal function in infants with sickle cell anemia: baseline data from the BABY HUG trial. J Pediatr (2010) 1.43
Biomarkers of splenic function in infants with sickle cell anemia: baseline data from the BABY HUG Trial. Blood (2011) 1.26
Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain? Curr Opin Hematol (2011) 1.18
Recruitment of infants with sickle cell anemia to a Phase III trial: data from the BABY HUG study. Contemp Clin Trials (2010) 1.07
Genetic modifiers of HbF and response to hydroxyurea in sickle cell disease. Pediatr Blood Cancer (2010) 1.03
Effect of hydroxyurea treatment on renal function parameters: results from the multi-center placebo-controlled BABY HUG clinical trial for infants with sickle cell anemia. Pediatr Blood Cancer (2012) 1.02
Influence of severity of anemia on clinical findings in infants with sickle cell anemia: analyses from the BABY HUG study. Pediatr Blood Cancer (2011) 1.02
Sickle cell nephropathy: challenging the conventional wisdom. Pediatr Nephrol (2011) 0.99
Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: results from the BABY-HUG Phase III Clinical Trial. Pediatr Blood Cancer (2011) 0.96
Developmental function in toddlers with sickle cell anemia. Pediatrics (2013) 0.88
Malnutrition in Sickle Cell Anemia: Implications for Infection, Growth, and Maturation. J Soc Behav Health Sci (2013) 0.86
Hereditary spherocytosis and partial splenectomy in children: review of surgical technique and the role of imaging. Pediatr Radiol (2010) 0.85
Hydroxyurea and growth in young children with sickle cell disease. Pediatrics (2014) 0.83
Should my child participate in this research study? Pediatr Blood Cancer (2010) 0.80
Hydroxurea and sickle cell disease: Its been a long, long time coming. Pediatr Blood Cancer (2010) 0.79
EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia. JMIR Res Protoc (2016) 0.77
Massive accidental overdose of hydroxyurea in a young child with sickle cell anemia. Pediatr Blood Cancer (2011) 0.75
Comparison of hematologic measurements between local and central laboratories: data from the BABY HUG trial. Clin Biochem (2012) 0.75
Interventions for chronic kidney disease in people with sickle cell disease. Cochrane Database Syst Rev (2017) 0.75
Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med (1994) 15.82
Effect of hydroxyurea on the frequency of painful crises in sickle cell anemia. Investigators of the Multicenter Study of Hydroxyurea in Sickle Cell Anemia. N Engl J Med (1995) 13.59
Pain in sickle cell disease. Rates and risk factors. N Engl J Med (1991) 9.75
Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev (2006) 4.46
Functional asplenia in sickle-cell anemia. N Engl J Med (1969) 3.50
Hydroxyurea: effects on hemoglobin F production in patients with sickle cell anemia. Blood (1992) 3.09
Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group. Blood (1999) 2.59
Abnormal adherence of sickle erythrocytes to cultured vascular endothelium: possible mechanism for microvascular occlusion in sickle cell disease. J Clin Invest (1980) 2.34
A two-year pilot trial of hydroxyurea in very young children with sickle-cell anemia. J Pediatr (2001) 2.22
Erythrocyte adherence to endothelium in sickle-cell anemia. A possible determinant of disease severity. N Engl J Med (1980) 2.14
Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood (2001) 2.12
Hydroxyurea for treatment of severe sickle cell anemia: a pediatric clinical trial. Blood (1996) 2.01
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
Sickle cell anemia as an inflammatory disease. J Clin Invest (2000) 1.70
Occlusion of large cerebral vessels in sickle-cell anemia. N Engl J Med (1972) 1.56
Incidence of cholelithiasis in sickle cell anemia using the ultrasonic gray-scale technique. J Pediatr (1980) 1.56
Respiratory mechanics in infants: physiologic evaluation in health and disease. American Thoracic Society/European Respiratory Society. Am Rev Respir Dis (1993) 1.56
The adhesive sickle erythrocyte: cause and consequence of abnormal interactions with endothelium, monocytes/macrophages and model membranes. Clin Haematol (1985) 1.51
Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer (2005) 1.51
Prevalence and clinical correlates of glomerulopathy in children with sickle cell disease. J Pediatr (2000) 1.48
Renal function studies in pediatrics. 1. Renal hemodynamics in children with sickle cell anemia. AMA Am J Dis Child (1952) 1.46
Hydroxyurea therapy in children severely affected with sickle cell disease. J Pediatr (1996) 1.44
Clinical and hematologic effects of hydroxyurea in children with sickle cell anemia. J Pediatr (1996) 1.44
Stroke in sickle cell disease: demographic, clinical, and therapeutic considerations. Semin Hematol (1991) 1.32
Chemical and functional analysis of hydroxyurea oral solutions. J Pediatr Hematol Oncol (2004) 1.30
Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics (1985) 1.30
Post-natal decline of fetal haemoglobin in homozygous sickle cell disease: relationship to parenteral Hb F levels. Br J Haematol (1982) 1.29
Cardiac abnormalities in children with sickle cell anemia. Chest (1990) 1.25
Early detection and the course of glomerular injury in patients with sickle cell anemia. Kidney Int (1996) 1.25
Hydroxyurea in children with sickle cell disease: impact on splenic function and compliance with therapy. J Pediatr Hematol Oncol (1998) 1.25
Fetal hemoglobin and clinical severity of homozygous sickle cell disease in early childhood. J Pediatr (1981) 1.21
Sickle cell nephropathy: new insights into its pathophysiology. Kidney Int (1985) 1.20
Hydroxyurea induction of hemoglobin F production in sickle cell disease: relationship between cytotoxicity and F cell production. Blood (1986) 1.08
Is hydroxyurea leukemogenic in children with sickle cell disease? Blood (2001) 1.06
Three-year follow-up of hydroxyurea treatment in severely ill children with sickle cell disease. The French Study Group on Sickle Cell Disease. J Pediatr Hematol Oncol (1997) 1.06
Renal lesions in sickle cell nephropathy in children. Nephron (1985) 1.06
Quantitative analysis of Howell-Jolly bodies in children with sickle cell disease. Exp Hematol (2007) 1.06
Gall stones in Jamaican children with homozygous sickle cell disease. Arch Dis Child (1989) 1.02
The relation between age and renal concentrating capacity in sickle cell disease and hemoglobin C disease. Clin Chim Acta (1970) 1.01
Use of hydroxyurea in children ages 2 to 5 years with sickle cell disease. J Pediatr Hematol Oncol (2000) 1.00
The research subject advocate at minority Clinical Research Centers: an added resource for protection of human subjects. Ethn Dis (2005) 0.86
Cardiac performance in children with homozygous sickle cell disease. J Am Coll Cardiol (1987) 0.80
Passive respiratory mechanics to assess lung function in infants. Monaldi Arch Chest Dis (1994) 0.79
Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med (2003) 13.84
Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation. Nat Med (2003) 8.95
Prognostic value of coronary vascular endothelial dysfunction. Circulation (2002) 7.68
Hydroxycarbamide in very young children with sickle-cell anaemia: a multicentre, randomised, controlled trial (BABY HUG). Lancet (2011) 7.30
Inhibitors of factor VIII in black patients with hemophilia. N Engl J Med (2009) 4.82
The risks and benefits of long-term use of hydroxyurea in sickle cell anemia: A 17.5 year follow-up. Am J Hematol (2010) 3.78
Improved survival of children and adolescents with sickle cell disease. Blood (2010) 3.30
Controlled trial of transfusions for silent cerebral infarcts in sickle cell anemia. N Engl J Med (2014) 3.25
Predisposition to atherosclerosis by infections: role of endothelial dysfunction. Circulation (2002) 3.09
Survival of children with sickle cell disease. Blood (2004) 2.84
Incidence of invasive pneumococcal disease among individuals with sickle cell disease before and after the introduction of the pneumococcal conjugate vaccine. Clin Infect Dis (2007) 2.60
Sustained long-term hematologic efficacy of hydroxyurea at maximum tolerated dose in children with sickle cell disease. Blood (2003) 2.55
Definitions of the phenotypic manifestations of sickle cell disease. Am J Hematol (2010) 2.55
Pulmonary hypertension and nitric oxide depletion in sickle cell disease. Blood (2010) 2.25
Elevated tricuspid regurgitant jet velocity in children and adolescents with sickle cell disease: association with hemolysis and hemoglobin oxygen desaturation. Haematologica (2009) 2.20
Adherence to antiretroviral therapy for pediatric HIV infection: a qualitative systematic review with recommendations for research and clinical management. Pediatrics (2007) 2.18
Silent cerebral infarcts occur despite regular blood transfusion therapy after first strokes in children with sickle cell disease. Blood (2010) 2.15
Hydroxyurea therapy lowers transcranial Doppler flow velocities in children with sickle cell anemia. Blood (2007) 2.13
Technology preview: X-ray fused with magnetic resonance during invasive cardiovascular procedures. Catheter Cardiovasc Interv (2007) 2.12
Childhood autoimmune cytopenia secondary to unsuspected common variable immunodeficiency. J Pediatr (2003) 2.11
A prospective newborn screening and treatment program for sickle cell anemia in Luanda, Angola. Am J Hematol (2013) 2.06
R2* magnetic resonance imaging of the liver in patients with iron overload. Blood (2009) 2.05
Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. Blood (2002) 2.02
MRI abnormalities of the brain in one-year-old children with sickle cell anemia. Pediatr Blood Cancer (2008) 2.01
Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. J Pediatr (2003) 2.00
Mutations in the gene encoding the lamin B receptor produce an altered nuclear morphology in granulocytes (Pelger-Huët anomaly). Nat Genet (2002) 1.99
Long-term hydroxyurea therapy for infants with sickle cell anemia: the HUSOFT extension study. Blood (2005) 1.99
Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation (2003) 1.98
Obesity development during adolescence in a biracial cohort: the NHLBI Growth and Health Study. Pediatrics (2002) 1.92
Stroke With Transfusions Changing to Hydroxyurea (SWiTCH): a phase III randomized clinical trial for treatment of children with sickle cell anemia, stroke, and iron overload. Pediatr Blood Cancer (2011) 1.89
In vitro modeling of the microvascular occlusion and thrombosis that occur in hematologic diseases using microfluidic technology. J Clin Invest (2011) 1.89
Design of the silent cerebral infarct transfusion (SIT) trial. Pediatr Hematol Oncol (2010) 1.87
Primary hemorrhagic stroke in children with sickle cell disease is associated with recent transfusion and use of corticosteroids. Pediatrics (2006) 1.84
Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury. Blood (2009) 1.83
Results of minimally toxic nonmyeloablative transplantation in patients with sickle cell anemia and beta-thalassemia. Biol Blood Marrow Transplant (2003) 1.81
Transcranial doppler ultrasonography (TCD) in infants with sickle cell anemia: baseline data from the BABY HUG trial. Pediatr Blood Cancer (2010) 1.75
Circumstances of death in adult sickle cell disease patients. Am J Hematol (2006) 1.74
Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore) (2004) 1.67
Impact of hydroxyurea on clinical events in the BABY HUG trial. Blood (2012) 1.66
Hospitalization for pain in patients with sickle cell disease treated with sildenafil for elevated TRV and low exercise capacity. Blood (2011) 1.64
Phase II study of clofarabine in pediatric patients with refractory or relapsed acute lymphoblastic leukemia. J Clin Oncol (2006) 1.62
Medical care utilization and mortality in sickle cell disease: a population-based study. Am J Hematol (2005) 1.61
Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.60
Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol (2005) 1.58
Organic anion transporting polypeptide 1B transporters modulate hydroxyurea pharmacokinetics. Am J Physiol Cell Physiol (2013) 1.56
Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin. Blood (2011) 1.54
Splenectomy in hereditary spherocytosis: Review of 1,657 patients and application of the pediatric quality indicators. Pediatr Blood Cancer (2009) 1.53
Statin attenuates increase in C-reactive protein during estrogen replacement therapy in postmenopausal women. Circulation (2002) 1.53
Silent Cerebral Infarct Transfusion (SIT) trial imaging core: application of novel imaging information technology for rapid and central review of MRI of the brain. J Digit Imaging (2008) 1.52
Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood (2002) 1.52
Genetic mapping and exome sequencing identify 2 mutations associated with stroke protection in pediatric patients with sickle cell anemia. Blood (2013) 1.52
Enalapril and hydroxyurea therapy for children with sickle nephropathy. Pediatr Blood Cancer (2005) 1.51
A pilot study of hydroxyurea to prevent chronic organ damage in young children with sickle cell anemia. Pediatr Blood Cancer (2009) 1.50
Risk of recurrent stroke in children with sickle cell disease receiving blood transfusion therapy for at least five years after initial stroke. J Pediatr (2002) 1.50
Pain and other non-neurological adverse events in children with sickle cell anemia and previous stroke who received hydroxyurea and phlebotomy or chronic transfusions and chelation: results from the SWiTCH clinical trial. Am J Hematol (2013) 1.49
Bleeding risks are higher in children versus adults given prophylactic platelet transfusions for treatment-induced hypoproliferative thrombocytopenia. Blood (2012) 1.48
Folylpolyglutamate synthetase gene transcription is regulated by a multiprotein complex that binds the TEL-AML1 fusion in acute lymphoblastic leukemia. Leuk Res (2010) 1.46
Bone marrow transplant options and preferences in a sickle cell anemia cohort on chronic transfusions. Pediatr Blood Cancer (2012) 1.46
Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. Biol Blood Marrow Transplant (2009) 1.46
Images in clinical medicine. Homozygous hemoglobin C disease. N Engl J Med (2004) 1.45
Translocation of sickle cell erythrocyte microRNAs into Plasmodium falciparum inhibits parasite translation and contributes to malaria resistance. Cell Host Microbe (2012) 1.45
Stroke Prevention Trial in Sickle Cell Anemia (STOP): extended follow-up and final results. Blood (2006) 1.45
The association between hydroxyurea treatment and pain intensity, analgesic use, and utilization in ambulatory sickle cell anemia patients. Pain Med (2011) 1.45
Predicting the effect of transfusing only phenotype-matched RBCs to patients with sickle cell disease: theoretical and practical implications. Transfusion (2002) 1.43